Related Experiment Video

Updated: Oct 17, 2026

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis
06:09

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis

Published on: July 18, 2017

Isepamicin versus amikacin for the treatment of acute pyelonephritis in children

D A Kafetzis1, H C Maltezou, M Mavrikou

  • 1Second Department of Pediatrics, University of Athens, P. and A. Kyriakou Children's Hospital, Athens, Greece. kafetzis@ath.forthnet.gr

International Journal of Antimicrobial Agents
|March 16, 2000
PubMed

Insights

Isepamicin and amikacin showed equal efficacy and safety in treating pediatric pyelonephritis. This study suggests isepamicin as a viable alternative for children

Area of Science:

  • Pediatric Nephrology
  • Infectious Diseases
  • Pharmacology

Background:

  • Pyelonephritis is a serious kidney infection in children.
  • Aminoglycosides are commonly used for treatment, but resistance is a growing concern.
  • Comparing novel aminoglycosides like isepamicin to established ones like amikacin is crucial.

Purpose of the Study:

  • To compare the efficacy and safety of isepamicin versus amikacin in treating pediatric pyelonephritis.
  • To evaluate clinical and bacteriological outcomes.
  • To assess serum drug levels and adverse events.

Main Methods:

  • A comparative study involving 16 children diagnosed with pyelonephritis.
  • Patients received either isepamicin or amikacin intravenously at 7.5 mg/kg every 12 hours for 10-14 days.
  • Urine cultures were analyzed, and clinical/bacteriological responses were monitored.

Main Results:

  • All patients (100%) in both the isepamicin and amikacin groups achieved successful treatment.
  • Escherichia coli was the causative pathogen in all cases.
  • No adverse events were reported in either treatment group, with comparable peak and trough serum levels observed.

Conclusions:

  • Isepamicin demonstrated equivalent efficacy and safety to amikacin in treating pediatric pyelonephritis.
  • Isepamicin presents a promising alternative, particularly in regions with high resistance rates to other aminoglycosides.
  • Further research may explore isepamicin's role in managing multidrug-resistant infections.

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...